Alzamend Neuro, Inc. (ALZN)
NASDAQ$0.67-0.02 (-2.90%)
Market Cap
$3.75M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
402 of 924
Rank in Industry
235 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ALZN Insider Trading Activity
ALZN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $1,292 | 4 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| AULT MILTON C III | 4 | $1,292 | 0 | $0 | $1,292 |
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, …
Insider Activity of Alzamend Neuro, Inc.
Over the last 12 months, insiders at Alzamend Neuro, Inc. have bought $1,292 and sold $0 worth of Alzamend Neuro, Inc. stock.
On average, over the past 5 years, insiders at Alzamend Neuro, Inc. have bought $4.74M and sold $63,434 worth of stock each year.
Highest buying activity among insiders over the last 12 months: AULT MILTON C III () — $1,292.
The last purchase of 75 shares for transaction amount of $206 was made by AULT MILTON C III () on 2024‑08‑06.
List of Insider Buy and Sell Transactions, Alzamend Neuro, Inc.
| 2024-08-06 | AULT MILTON C III | 75 0.0107% | $2.75 | $206 | -42.79% | |||
| 2024-07-31 | AULT MILTON C III | 25 0.0034% | $3.74 | $93 | -62.04% | |||
| 2024-04-19 | AULT MILTON C III | 1,000 0.0148% | $0.69 | $688 | -75.15% | |||
| 2024-04-01 | AULT MILTON C III | 334 0.005% | $0.91 | $304 | -80.34% | |||
| 2024-01-05 | AULT MILTON C III | 2,000 0.0308% | $1.06 | $2,127 | -58.00% | |||
| 2024-01-05 | AULT MILTON C III | 5,000 0.0737% | $1.02 | $5,093 | -58.00% | |||
| 2023-12-26 | AULT MILTON C III | 10 percent owner | 500 0.007% | $0.90 | $450 | -53.77% | ||
| 2023-12-22 | AULT MILTON C III | 10 percent owner | 200 0.0029% | $0.92 | $185 | -52.22% | ||
| 2023-09-26 | Katzoff David J | Chief Financial Officer | 53,000 0.0564% | $0.19 | $10,234 | -69.37% | ||
| 2023-05-24 | AULT MILTON C III | 10 percent owner | 18,000 0.0185% | $0.59 | $10,705 | -86.53% | ||
| 2023-04-28 | Jackman Stephan | Chief Executive Officer | 37,000 0.0372% | $0.54 | $19,999 | -67.51% | ||
| 2023-03-22 | McGrath Lynne Fahey | director | 10,000 0.0101% | $0.43 | $4,350 | -47.91% | ||
| 2023-03-17 | AULT MILTON C III | 10 percent owner | 5,000 0.0055% | $0.43 | $2,149 | -42.00% | ||
| 2023-03-16 | AULT MILTON C III | 10 percent owner | 4,000 0.0045% | $0.50 | $2,006 | -48.95% | ||
| 2023-02-15 | AULT MILTON C III | 10 percent owner | 1,000 0.001% | $0.60 | $597 | -50.44% | ||
| 2022-12-28 | AULT MILTON C III | director | 3,100 0.0033% | $0.56 | $1,745 | -8.49% | ||
| 2022-12-27 | AULT MILTON C III | director | 900 0.0009% | $0.59 | $532 | -18.01% | ||
| 2022-12-21 | AULT MILTON C III | director | 5,000 0.0054% | $0.81 | $4,050 | -35.56% | ||
| 2022-12-19 | AULT MILTON C III | director | 23,000 0.023% | $0.82 | $18,813 | -40.35% | ||
| 2022-12-16 | AULT MILTON C III | director | 20,000 0.0218% | $0.90 | $17,960 | -40.63% |
Total: 115
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| AULT MILTON C III | 77268 1.4223% | $53,291.74 | 105 | 4 | <0.0001% | |
| Katzoff David J | Chief Financial Officer | 81000 1.4909% | $55,865.70 | 1 | 0 | <0.0001% |
| Jackman Stephan | Chief Executive Officer | 45500 0.8375% | $31,381.35 | 1 | 0 | |
| McGrath Lynne Fahey | director | 10000 0.1841% | $6,897.00 | 1 | 1 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
Alzamend Neuro, Inc. (ALZN) | $18,881,323 | 88 | -48.96% | $3.75M |
$296,936 | 37 | -18.12% | $4.42M | |
$1,616,354 | 20 | -12.22% | $3.22M | |
$960,082 | 17 | -6.29% | $3.61M | |
$1,558,469 | 16 | -26.98% | $4.4M |
ALZN Institutional Investors: Active Positions
| Increased Positions | 9 | +60% | 93,316 | +221.64% |
| Decreased Positions | 4 | -26.67% | 22,088 | -52.46% |
| New Positions | 8 | New | 93,285 | New |
| Sold Out Positions | 3 | Sold Out | 18,309 | Sold Out |
| Total Postitions | 20 | +33.33% | 113,330 | +169.18% |
ALZN Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Geode Capital Management, Llc | $28.00 | 0.67% | 33,540 | +33,540 | New | 2024-12-31 |
| Citadel Advisors Llc | $25.00 | 0.61% | 30,638 | +30,638 | New | 2024-12-31 |
| Truist Financial Corp | $13.00 | 0.31% | 15,498 | 0 | 0% | 2024-12-31 |
| Renaissance Technologies Llc | $12.00 | 0.3% | 15,000 | +15,000 | New | 2024-12-31 |
| Virtu Financial Llc | $10.00 | 0.25% | 12,719 | +12,719 | New | 2024-12-31 |
| Blackrock, Inc. | $3.00 | 0.08% | 3,973 | 0 | 0% | 2024-12-31 |
| Ubs Group Ag | $1.00 | 0.02% | 820 | +820 | New | 2024-12-31 |
| Citigroup Inc | $0 | 0.01% | 544 | +544 | New | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $0 | 0.01% | 388 | -3,779 | -90.69% | 2024-12-31 |
| Bank Of America Corp /De/ | $0 | <0.01% | 136 | +31 | +29.52% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.